Literature DB >> 23104253

Mesenchymal stem cells promote a primitive phenotype CD34+c-kit+ in human cord blood-derived hematopoietic stem cells during ex vivo expansion.

Viviana M Rodríguez-Pardo1, Jean Paul Vernot.   

Abstract

The purpose of this study was to evaluate the influence of bone marrow-mesenchymal stem cells (BM-MSC) and exogenously added cytokines on the proliferation, primitive cell subpopulation maintenance (including the c-kit+ marker) and clonogenic capacity of hematopoietic stem cells (HSC). BM-MSC were collected from volunteer donors, isolated and characterized. Umbilical cord blood (UCB) samples were collected from healthy full-term deliveries. UCB-CD34+ cells were cultured in the presence or absence of BM-MSC and/or cytokines for 3 and 7 days. CD34+ cell proliferation was evaluated using the CSFE method and cell phenotype was determined by CD34, c-kit, CD33, CD38, HLA-DR, cyCD22 and cyCD3 detection. Cell clonogenic ability was also assessed. Exogenously added SCF, TPO and FLT3L increased CD34+ cell proliferation in the presence or absence of BM-MSC, but with concomitant cell differentiation. Without any added cytokines, BM-MSC are able to increase the percentage of primitive progenitors as evaluated by c-kit expression and CFU-GEMM increase. Interestingly, this latter effect was dependent on both cell-cell interactions and secreted factors. A 7-day co-culture period will be optimal for obtaining an increased primitive HSC level. Including c-kit as a marker for primitive phenotype evaluation has shown the relevance of BM-MSC and their secreted factors on UCB-HSC stemness function. This effect could be dissociated from that of the addition of exogenous cytokines, which induced cellular differentiation instead.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104253      PMCID: PMC6275752          DOI: 10.2478/s11658-012-0036-1

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


Supplementary material, approximately 393 KB.
  73 in total

1.  Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

Authors:  H Glimm; W Eisterer; K Lee; J Cashman; T L Holyoake; F Nicolini; L D Shultz; C von Kalle; C J Eaves
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  CD117+ stem cells play a key role in therapeutic angiogenesis induced by bone marrow cell implantation.

Authors:  Tao-Sheng Li; Kimikazu Hamano; Masahiko Nishida; Masanori Hayashi; Hiroshi Ito; Akihito Mikamo; Masunori Matsuzaki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-09       Impact factor: 4.733

Review 3.  Cord blood banking for clinical transplantation.

Authors:  P Rubinstein
Journal:  Bone Marrow Transplant       Date:  2009-10-05       Impact factor: 5.483

4.  Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor population.

Authors:  Q L Hao; F T Thiemann; D Petersen; E M Smogorzewska; G M Crooks
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

5.  Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

Authors:  M Bhatia; J C Wang; U Kapp; D Bonnet; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

6.  Identification of human T-lymphoid progenitor cells in CD34+ CD38low and CD34+ CD38+ subsets of human cord blood and bone marrow cells using NOD-SCID fetal thymus organ cultures.

Authors:  C Robin; A Bennaceur-Griscelli; F Louache; W Vainchenker; L Coulombel
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

Review 7.  The transcriptional basis of adipocyte development.

Authors:  Evan D Rosen
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005-07       Impact factor: 4.006

8.  Co-culture of cord blood CD34(+) cells with human BM mesenchymal stromal cells enhances short-term engraftment of cord blood cells in NOD/SCID mice.

Authors:  X M Fei; Y J Wu; Z Chang; K R Miao; Y H Tang; X Y Zhou; L X Wang; Q Q Pan; C Y Wang
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

9.  Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells.

Authors:  H J McKenna; P de Vries; K Brasel; S D Lyman; D E Williams
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

10.  Effects of thrombopoietin on the proliferation and differentiation of primitive and mature haemopoietic progenitor cells in cord blood.

Authors:  L F Schipper; A Brand; N C Reniers; C J Melief; R Willemze; W E Fibbe
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

View more
  15 in total

1.  Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture.

Authors:  Dandan Li; Grace Chiu; Brea Lipe; Richard A Hopkins; Jacquelyn Lillis; John M Ashton; Soumen Paul; Omar S Aljitawi
Journal:  Blood Adv       Date:  2019-04-09

Review 2.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

3.  Impact of donor characteristics on the quality of bone marrow as a source of mesenchymal stromal cells.

Authors:  Emilia Barreto-Durán; Claudia Camila Mejía-Cruz; Efrain Leal-García; Rafael Pérez-Núñez; Viviana Marcela Rodríguez-Pardo
Journal:  Am J Stem Cells       Date:  2018-12-01

Review 4.  Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects.

Authors:  Mohaddeseh Rahbaran; Angelina Olegovna Zekiy; Mahta Bahramali; Mohammadsaleh Jahangir; Mahsa Mardasi; Delaram Sakhaei; Lakshmi Thangavelu; Navid Shomali; Majid Zamani; Ali Mohammadi; Negin Rahnama
Journal:  Cell Mol Biol Lett       Date:  2022-07-16       Impact factor: 8.702

Review 5.  Mesenchymal stromal cell-derived extracellular vesicles: novel approach in hematopoietic stem cell transplantation.

Authors:  Davod Pashoutan Sarvar; Hosein Effatpanah; Parvin Akbarzadehlaleh; Karim Shamsasenjan
Journal:  Stem Cell Res Ther       Date:  2022-05-16       Impact factor: 8.079

6.  Interleukin 7 plays a role in T lymphocyte apoptosis inhibition driven by mesenchymal stem cell without favoring proliferation and cytokines secretion.

Authors:  Marilia Normanton; Heliene Alvarenga; Nelson Hamerschlak; Andreza Ribeiro; Andrea Kondo; Luiz Vicente Rizzo; Luciana Cavalheiro Marti
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

7.  Loss of quiescence and self-renewal capacity of hematopoietic stem cell in an in vitro leukemic niche.

Authors:  Natalia-Del Pilar Vanegas; Jean-Paul Vernot
Journal:  Exp Hematol Oncol       Date:  2017-01-10

8.  Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.

Authors:  Daniel V Brown; Gulay Filiz; Paul M Daniel; Frédéric Hollande; Sebastian Dworkin; Stephanie Amiridis; Nicole Kountouri; Wayne Ng; Andrew P Morokoff; Theo Mantamadiotis
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

9.  Phenotypic and Functional Alterations of Hematopoietic Stem and Progenitor Cells in an In Vitro Leukemia-Induced Microenvironment.

Authors:  Jean-Paul Vernot; Ximena Bonilla; Viviana Rodriguez-Pardo; Natalia-Del Pilar Vanegas
Journal:  Int J Mol Sci       Date:  2017-02-14       Impact factor: 5.923

10.  3D Multicellular Spheroid for the Study of Human Hematopoietic Stem Cells: Synergistic Effect Between Oxygen Levels, Mesenchymal Stromal Cells and Endothelial Cells.

Authors:  Emilia Barreto-Duran; Claudia Camila Mejia-Cruz; Luis Fernando Jaramillo-Garcia; Efrain Leal-Garcia; Alfonso Barreto-Prieto; Viviana Marcela Rodriguez-Pardo
Journal:  J Blood Med       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.